INBS | Intelligent Bio Solutions Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.2400 - 1.3600
52 Week Range	1.0000 - 11.70
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	155,298
Average Volume	137,255
Shares Outstanding	4,386,820
Market Cap	5,702,866
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2020-12-23

Valuation
Profitability
Growth
Health
P/E Ratio	-0.57
Forward P/E Ratio	N/A
EPS	-2.30
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	50
Country	USA
Website	INBS

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

INBS's peers: ISPC, NDRA, OCX, PRPH, STRR, TTOO, BIAF

*Chart delayed

Analyzing fundamentals for INBS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see INBS Fundamentals page.

Watching at INBS technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on INBS Technicals page.